Harvey Rubinson

Harvey Rubinson is an accomplished turnaround consultant and finance executive with extensive experience in leadership roles across various industries. Currently serving as a Turnaround Consultant at RubinsonTurnaround and Associates since January 2020, and as CFO at Micelle BioPharma since July 2018, Harvey is instrumental in developing a drug for Sickle Cell Anemia. As CEO of HCRTurnaround Associates LLC since March 2011, recent engagements include roles as Interim CFO and Operational Improvement Advisor for multiple companies. Harvey's prior experience includes serving as Director at AlixPartners, where key roles included Interim CFO for Bally Fitness, and Managing Director at XRoads Solutions Group, handling a range of financial and operational advisory positions. A graduate of The Wharton School with an MBA in Finance and Marketing, Harvey Rubinson brings a wealth of expertise in financial turnaround and operational improvement.